Raptor Pharmaceutical Inc. (RPTP) Licenses Intellectual Property for Rett Syndrome From French Research Institutes
5/7/2013 9:35:12 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
NOVATO, Calif., May 7, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) announced that it has licensed pending patents related to the use of cysteamine for the treatment of Rett syndrome and associated disorders of methyl-CpG binding protein 2 (MECP2). Under terms of the agreement, Raptor receives exclusive global rights to develop and commercialize cysteamine and related compounds to treat MECP2-associated disorders. Raptor's license agreement is with the Technology Transfer Accelerator of South Eastern France (SATT Sud Est) that represents the French medical research organizations where the technology was invented, including the Institut Curie, INSERM and Aix-Marseille Université.
Help employers find you! Check out all the jobs and post your resume.